News | May 16, 2010

Cryoablation Trial Demonstrates Decrease in AF Symptoms

May 17, 2010 – New STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial data showing the number of paroxysmal atrial fibrillation (AF) patients reporting AF symptoms declined by 80 percent after treatment with the Arctic Front Cardiac CryoAblation Catheter System. Additionally, as reported in the quality-of-life questionnaire results, all patients randomized and treated with the catheter system reported significant improvements in physical and mental quality-of-life factors.

These data were presented as a late breaking clinical trial at Heart Rhythm 2010 last week in Denver. The cryoablation system is commercially available in Europe and is under investigational use in the United States.

“The significant reduction in AF-related symptoms observed in this trial demonstrates the potential relief that cryoablation therapy can provide to patients suffering from symptomatic paroxysmal AF,” said Jeremy Ruskin, M.D., chair of the STOP AF trial steering committee, director of cardiac arrhythmia service at Massachusetts General Hospital. He also is associate professor of medicine at Harvard Medical School in Boston.

The number of patients randomized to cryoablation in the STOP AF trial who reported AF symptoms declined from 100 percent at baseline (pretreatment) to 20 percent at 12 months after cryoablation treatment. Specifically, when compared at baseline and 12 months, there was a reduction in the number of study participants who reported the following six symptom categories: palpitations (86 to 25 percent), fatigue (76 to 13 percent), rapid heart beat (66 to 16 percent), dyspnea, or difficulty breathing (54 to 9 percent), dizziness (48 to 9 percent), and syncope, or fainting (4 to 1 percent). To some AF patients, these symptoms can be debilitating.

About STOP AF
The STOP AF pivotal clinical trial enrolled 245 patients at 26 U.S. and Canadian centers and studied the safety and effectiveness of the Medtronic Arctic Front Cardiac CryoAblation Catheter System in paroxysmal AF patients as compared to drug therapy. All primary safety and effectiveness endpoints in the trial were met. These results are part of the premarket approval submission under regulatory review by the U.S. Food and Drug Administration (FDA).

Cryoablation Catheter System
The catheter is designed to be used with fluoroscopy and does not require the use of complex, three-dimensional mapping systems. The technologies used in the STOP AF trial include:

• The catheter inflates and fills with coolant to ablate the tissue where the pulmonary veins enter the left atrium
• The FlexCath steerable sheath helps deliver and position the cryocatheter in the left atrium
• The Freezor Max Cardiac CryoAblation Catheter is a single-point catheter used to provide additional ablations, as needed
• The CryoConsole houses the coolant, electrical and mechanical components that run the catheters during a cryoablation procedure

The Arctic Front Cardiac CryoAblation system is investigational and not currently available for sale in the United States.

For more information: www.medtronic.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init